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Introduction
The advent of tyrosine kinase inhibitors (TKIs) has dramat-
ically changed the outcome of chronic myeloid leukemia
(CML). Imatinib has induced rates of over 80% complete
cytogenetic response (CCyR) and 70% major molecular
response (MMR).1,2 Despite this success, about 20% of
patients demonstrate primary or acquired resistance to this
drug.3,4 Several mechanisms may contribute to this phenome-
non,5-7 but the onset of mutations has been reported as a
major determinant of resistance.8-10 With 2nd generation TKIs
(2nd TKIs), dasatinib or nilotinib, it has been demonstrated that
approximately 50% of patients failing to respond to previous
treatments can be rescued.11-15 Few reports have described the
outcome of patients who, after failing to respond to 2nd TKIs,
were treated with third-line TKI.8,11 We report the long-term
outcome of a large series of CML patients who received
dasatinib or nilotinib as third-line TKI therapy.
Design and Methods
Patients being sequentially treated with 3 TKIs were recruited by 18
Italian centers. Patients were strictly monitored according to European
Leukemia Net (ELN) recommendations5 at different time points. In
cases of resistance, mutational analysis was performed with direct
sequencing and DHPLC, before starting 2nd TKIs. Patients were
switched to dasatinib or nilotinib in cases of failure or severe intoler-
ance and responses were monitored according to 2009 ELN provision-
al criteria for 2nd TKI after imatinib resistance. Intolerance was defined
as grade 3-4 hematologic or non-hematologic toxicity or persistent
grade 2, despite best supportive therapies. Response criteria were
defined according to ELN recommendations5 (Table 1). Univariate and
multivariate logistical models were used to evaluate the effects of vari-
ables (gender, age, CyR to imatinib, etc.) on CyR to third-line TKI
therapy (Table 2). Covariates in the multivariate logistical regression
models were chosen by stepwise-with-backward elimination variable
selection procedures. P values less than 0.05 were considered statisti-
cally significant. The analyses were performed using SPSS software
for Windows, version 13.0. Survival probabilities were estimated by
the Kaplan-Meier method, and compared by the log rank test.
Ethics 
This study was approved by the Ethical Committee at the
Policlinico of Bari, Italy.
Results and Discussion
A total of 82 patients were recruited and treated sequential-
ly with TKIs: median age was 62 years (range 33-85); 29 were
male and 53 female. Sixty-two patients (75.6%) had received
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There have been few reports of a response to dasatinib or nilotinib after failure of two prior sequential tyrosine
kinase inhibitors. We report the outcome of 82 chronic phase patients who received nilotinib or dasatinib as
third-line alternative tyrosine kinase inhibitor therapy. Thirty-four patients failed to respond to nilotinib and
were started on dasatinib as third-line tyrosine kinase inhibitor therapy while 48 patients were switched to nilo-
tinib after dasatinib failure. Overall, we obtained a cytogenetic response in 32 of 82 patients and major molecular
response in 13 patients; disease progression occurred in 12 patients. At last follow up, 70 patients (85.4%) were
alive with a median overall survival of 46 months. Our results show that third-line tyrosine kinase inhibitor ther-
apy in chronic myeloid leukemia patients after failure of two prior sequential tyrosine kinase inhibitors may
induce a response that, in some instances, could prolong overall survival and affect event-free survival.
ABSTRACT
prior interferon-alpha before starting on imatinib; 20
patients (24.4%) received imatinib as first-line therapy.
Sokal’s risk evaluation at baseline showed that 27% of
patients were low, 25% intermediate and 48% high risk.
No patient had undergone allogeneic transplant (HSCT)
before receiving TKIs. At the start of imatinib, all patients
were in chronic phase (CP). Median time on imatinib ther-
apy was 45 months (range 4-101), and median imatinib
dose was 400 mg/day. Ten patients received high-dose
imatinib for resistance to standard dosage. Best overall
response to imatinib was MMR in 6 patients (7.3%),
CCyR in 19 patients (23.2%), partial CyR (PCyR) in 21
patients (25.6%), minor CyR (mCyR) in 10 patients
(12.2%), only complete hematologic response (CHR)
without any CyR in 21 patients (25.6%). No response
(NR) was observed in 5 patients (6.1%). Imatinib was dis-
continued in 74 patients (90.2%) due to resistance and in
8 (9.8%) due to intolerance.
Responses to second-line TKIs 
Thirty-four patients received nilotinib as second-line
TKI therapy at a starting dose of 400 mg BID (Group A):
30 of 34 (88.2%) patients were in CP, 2 (5.9%) in acceler-
ated phase, and 2 (5.9%) in blastic phase (BP). Thirty-two
patients were switched to nilotinib due to resistance, and
2 to intolerance to imatinib. Median time of imatinib treat-
ment before the switch was 47 months (range 6-67).
Mutational screening at baseline, performed in 19
patients, revealed that 10 patients had developed muta-
tions before starting treatment, probably due to the long
duration of the disease (Online Supplementary Table S1).
The most frequent mutations detected were F317L(2),
A269S, H295P+F311L+Y320H, M244V, M351T+F359C,
E255K(2), Y253H, S417F. Twenty-four patients (70.6%)
received no other treatment before starting nilotinib,
whereas 7 patients (20.6%) received hydroxyurea (HU), 2
patients (5.9%) high-dose imatinib, one patient (2.9%)
HSCT. Best response to nilotinib was CCyR in 7 patients
(20.6%), PCyR in 5 patients (14.8%), mCyR in 6 patients
(17.6%), CHR in 8 patients (23.5%), and NR in 8 patients
(23.5%). None of the treated patients obtained MMR.
Median time on second-line nilotinib was 30 months
(range 1-36).
Forty-eight patients were treated with dasatinib as sec-
ond-line TKI therapy (Group B): 42 of 48 (87.5%) patients
were in CP, 5 (10.4%) in accelerated phase, one (2.1%) in
BP. Twenty patients (41.7%) received a starting dose of 70
mg BID, the remaining patients received doses of 50 mg
BID or 100 mg QD. In 35 patients (73%), no interval treat-
ment was given between the discontinuation of imatinib
and the start of dasatinib, whereas one patient received
IFNα, one chemotherapy (cytosine-arabinoside), 3
patients high-dose imatinib, 6 patients HU, and 2 patients
underwent HSCT. Ten patients (29.4%) were found to
have mutations before starting dasatinib: the most com-
mon mutations were M244V(3), F359V(2)+E450G,
N322D+K400E+E409G+K467R, T315A+P309R, M351K,
M351V, D276G. Forty-two patients were considered
resistant and 6 intolerant to imatinib. Best response to
dasatinib included MMR in 11 patients (22.9%), CCyR in
9 patients (18.7%), PCyR in 4 patients (8.3%), mCyR in 3
patients (6.3%), only CHR in 13 patients (27.1%), and no
response in 8 patients (16.7%). Median time on second-
line dasatinib was 13 months (range 4-59) (Table 1).
Efficacy and safety of third-line TKIs
Group A was made up of 34 patients: 30 patients were
in CP (88.2%), one patient in accelerated phase (2.9%) and
3 patients in BP (8.8%). These patients were started on
dasatinib as third-line TKI therapy. Fourteen patients
(41%) were switched to dasatinib for intolerance; 17
(50%) patients were considered resistant to nilotinib: 8
patients were screened for mutations and these were
found in 4 of them (T315I, F317L, F359C, E255V). Three
patients were considered both intolerant and resistant:
none of these patients presented mutations. Eighteen
patients were evaluated for mutational screening at the
time of the switch and mutations were identified in 8: 5
new mutations (F359V, T315I, F359V, Y253H (2)+F359V)
and 3 confirmed mutations (A269S, F317L, F359C).
Group B was made up 48 patients: 38 patients in CP
(79%), 8 patients in accelerated phase (16.6%) and 2
patients in BP (4%). These patients were started on nilo-
tinib as third-line TKI therapy. Twenty-four patients
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Table 1. Baseline patients’ characteristics.*
Parameter                                              GROUP A                  GROUP B
Number of patients                                             34                                   48
Median age (years; range)                         60 (43-85)                    60 (33-80)
Gender (male/female)                                      9/25                               20/28
Sokal Risk 
Low                                                                         9                                    14
Intermediate                                                        8                                    11
High                                                                       17                                   23
Interferon-alpha therapy 
Yes                                                                        28                                   34
No                                                                          6                                    14
Best response to imatinib 
NR                                                                          2                                     3
CHR                                                                       9                                    12
mCyR                                                                     4                                     6
PCyR                                                                      9                                    12
CCyR                                                                      9                                    10
MMR                                                                      1                                     5
Reasons for discontinuation of imatinib
Resistance                                                          32                                   42
Intolerance                                                          2                                     6
Stage at the time of starting second-line TKI therapy
CP                                                                          30                                   42
AP                                                                           2                                     5
BC                                                                          2                                     1
Response to second-line TKI therapy               
NR                                                                          8                                     8
CHR                                                                       8                                    13
mCyR                                                                     6                                     3
PCyR                                                                      5                                     4
CCyR                                                                      7                                     9
MMR                                                                     -                                    11
Reasons for failure of second-line TKI therapy
Resistance                                                          17                                   24
Intolerance                                                         14                                   24
Both                                                                       3                                     -
Disease stage at the time of starting third-line TKI
CP                                                                           30                                   38
AP                                                                            1                                     8
BC                                                                           3                                     2
*CP: chronic phase;  AP: accelerated phase; BP: blastic phase; NR: no response; mCyR:
minor cytogenetic response; PCyR: partial cytogenetic response; CCyR: complete cyto-
genetic response; MMR: major molecular response. 
(50%) were considered intolerant to dasatinib: among
these, mutations were found in 6 of 18 patients tested
(F317L(2), M244V(2), L387M, M351T). Twenty-four
patients were considered resistant to dasatinib and
switched to nilotinib: 8 of 18 patients tested presented a
mutation at the time of the switch (F317L(3), M244V(2),
M318T, T315I, G250E). Twenty-four patients were taken
off because of intolerance (most common side effects
were pleural effusion and thrombocytopenia). Overall,
best response to third-line TKI treatment was MMR in 13
patients (15.9%), CCyR in 14 patients (17.1%), PCyR in
12 patients (14.6%), mCyR in 6 patients (7.3%), only CHR
in 26 patients (31.7%). Twelve patients  (14.6%) did not
achieve any response. In Group A, treatment was discon-
tinued in 14 of 34 (41.2%) patients because of toxicity. In
Group B, 24 patients of 48 (50%) experienced severe toxi-
city requiring treatment discontinuation. Two new muta-
tions (F317L, E255V) emerged with dasatinib and 2 new
mutations (Y253H, G250E) with nilotinib as third-line TKI
therapy; 9 patients (26%) in group A and 3 patients (21%)
in group B had disease transformation. After a median fol-
low up of 14 months (range 2-37), 50 patients (48 CP and
2 accelerated phase) are still in treatment (33 patients with
nilotinib and 17 with dasatinib). At last follow up, 70
patients (85.4%) were still alive with a median overall sur-
vival of 46 months (range 15-300). Twelve patients died
(14.6%) of disease progression associated with T315I
development.
Univariate and multivariate analyses were performed to
identify predictive factors associated with the achieve-
ment of CyR to third-line TKI therapy (Table 2). Patients
who did achieve a CyR on imatinib or with low and inter-
mediate Sokal risk had a higher probability of achieving
CyR with third-line TKI therapy (P<0.001). The presence
of a mutation before starting a third-line TKI therapy did
not affect the response. During follow up, 13 (15.9%)
patients failed to respond to third-line TKI therapy and 12
(14.6%) died of disease progression. The 30-month prob-
abilities of event-free survival (EFS) and overall survival
(OS) were 76.4% in CP patients and 16.5% in AP
(advanced phase: accelerated phase+BP) (P<0.001) and
98.5% in CP patients and 76.1% in AP (P<0.001), respec-
tively (Figure 1A and B). 
Although the use of imatinib has improved cytogenetic
and molecular responses as compared to previously avail-
able therapies,16,17 approximately 30-50% of patients did
not achieve a CCyR within 12 months of therapy.
Furthermore, IRIS results at 8-year follow up showed that
17% of patients had primary resistance and 15% lost a
previously obtained CyR.18,19 From sponsored trials, 40-
50% of resistant patients can be rescued by 2nd generation
TKIs, but  patients who failed to respond to first-line are
CML patients treated with nilotinib or dasatinib 
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Table 2. Univariate and multivariate regression analysis of factors
affecting CyR to third-line TKIs*.
Univariate logistical model Multivariate logistical model§
Coefficient SD P Coefficient SD P
(b) (b)
Age -0.011 0.158 0.943 ‡ ‡ ‡
<65 vs. ≥65 years
Gender -0.787 0.168 0.640 ‡ ‡ ‡
Male vs. female
Sokal risk -0.390 0.139 0.006 -0.448 0.0952 <.001
High vs. intermediate/low
CyR to imatinib 0.572 0.189 0.003 0.552 0.0952 <.001
(at least mCyR)
CyR to second TKI 0.0724 0.197 0.714 ‡ ‡ ‡
Mutations 0.675 0.190 0.50 ‡ ‡ ‡
Resistance -0.346 0.194 0.079 ‡ ‡ ‡
Intolerance -0.356 0.187 0.60 ‡ ‡
*CyR: cytogenetic response; mCyR: minor cytogenetic response; TKI: tyrosine kinase
inhibitor; §model with variables selected by stepwise procedure; ‡variables deleted by
stepwise procedure. 
Figure 1. Kaplan-Meier estimates for overall survival (OS) and event-free survival (EFS) in CML patients treated with third-line tyrosine kinase
inhibitor therapy after failure of two prior sequential tyrosine kinase inhibitors. (A) OS of patients in chronic phase (CP) and advanced phase
(AP: accelerated phase + blastic phase). The 30-month probabilities of OS were 98.5% in CP patients and 76.1% in AP (P<0.001). (B) EFS
of patients in chronic phase (CP) and advanced phase (AP: accelerated phase + blastic phase). The 30-month probabilities of EFS were
76.4% in CP patients and 16.5% in AP (P<0.001).
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at risk of losing the response also to second-line TKIs.14,15
Tam et al. suggested that patients treated with 2nd TKIs had
a higher progression rate if they did not obtain an MCyR
within 12 months or were completely Ph+ after 3 or 6
months.4 Limited data have been published on the use of
nilotinib or dasatinib after failure of two prior TKIs. Garg
et al. reported 48 CML patients, 25 in CP and 23 in accel-
erated phase/BP (34 treated with dasatinib after
imatinib/nilotinib failure and 14 with nilotinib after ima-
tinib/dasatinib failure):8 with third-line therapy, CP
patients obtained MMR (5 patients) and CCyR (3 patients)
as best response, the latter showing a median duration of
16 months. Even in advanced phases of disease, in terms
of best response, 2 patients achieved MMR and 3 patients
a CCyR. After a median follow up of 16 months, 13
patients were still continuing therapy and median EFS was
13 months. Quintas-Cardama and colleagues reported a
single center experience of the use of dasatinib after failure
of previous imatinib and nilotinib in 23 patients (19
patients in advanced phases), obtaining a CCyR rate of
30%.11 Nilotinib was reported to overcome imatinib and
dasatinib failure in 67 patients (27 CP, 15 accelerated phase
and 25 BP): in CP patients the MCyR rate was 32%, where-
as 23% of the accelerated phase patients returned to CP. Of
20 evaluable BP patients, 15% had a CHR and 5% returned
to CP.20 The results of the present study, confirm the
impressive efficacy of both agents used as rescue therapy
after failure of two prior TKIs, but highlighted some impor-
tant issues. Firstly, the median duration of responses
obtained with a third-line TKI therapy is not so long.
Secondly, as shown also in our experience, the frequency
of emerging mutations in patients treated sequentially with
different TKIs is higher. In fact, two new mutations with
an IC50 of more than 3 nM (F317L, E255V) emerged with
dasatinib and two new mutations with an IC50 of more
than 150 nM (Y253H, G250E) emerged with nilotinib as
third-line TKI therapy, reflecting the use of sequential TKI
therapy. In our experience, approximately 14% of patients
died of progression associated with the onset of a T315I; as
also reported elsewhere, sequential treatment with several
TKIs could cause selection of this mutation.21-23 We
observed a similar toxicity rate in third-line TKI therapy
with both agents (41.2% discontinuation of nilotinib and
50% of dasatinib). However, in spite of the presence of
side effects, 70 of 82 patients are still alive with a median
OS of 46 months. Among patients who failed to respond
to dasatinib or nilotinib or with a T315I mutation, recent
results showed that ponatinib, a 3rd generation TKI, could
have anti-leukemic activity and may also act as a bridge to
HSCT.24 In conclusion, our results show that a third-line
TKI therapy, after failure of two prior TKIs, might induce a
response that, although transient in some instances, could
prolong OS and, in particular, delay the onset of events.
Third-line TKI therapy could be a valid therapeutic option
for some categories of patients not eligible for HSCT, such
as elderly patients with comorbidities.
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